BioSpectrum the business of Bio & Health Sciences ASIA EDITION

PharmaJet, Abnova to use needle-free injection technology for COVID-19 vaccine

May 25, 2020 | News

To deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2



US based PharmaJet®, the maker of innovative, needle-free injection technology, has announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world's largest antibody manufacturer, based in Taiwan.

Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.

"We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx™ Immune platform," said Dr. Wilber Huang, President and CEO, Abnova. "We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome."